Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Algernon Pharmaceuticals Inc Class A (AGN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.105 0.000    0.00%
29/04 - Closed. Currency in CAD ( Disclaimer )
Type:  Equity
Market:  Canada
  • Volume: 0
  • Bid/Ask: 0.100 / 0.120
  • Day's Range: 0.105 - 0.125
Algernon Pharma 0.105 0.000 0.00%

Algernon Pharmaceuticals Inc Class A Company Profile

 
Get an in-depth profile of Algernon Pharmaceuticals Inc Class A, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada and Australia. The company’s pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

Contact Information

Address 601 West Broadway Suite 400
Vancouver, V5Z 4C2
Canada
Phone 604-398-4175
Fax -

Top Executives

Name Age Since Title
David John Nutt - - Member of Medical & Scientific Advisory Board
Rajpaul Attariwala 55 2015 Independent Director
Jacky Smith - 2020 Member of Medical & Scientific Advisory Board
Christopher J. Moreau 58 2018 CEO & Director
Martin Kolb - 2019 Member of Medical & Scientific Advisory Board
Anthony Rudd - - Member of Medical & Scientific Advisory Board
Howard W. Gutman 65 2020 Director
Mark Williams 51 2018 Director
Mark Swaim - 2020 Member of Medical & Scientific Advisory Board
Harold J. F. Bloomfield 78 2021 Independent Chairman of the Board
David L. Brody - - Member of Medical & Scientific Advisory Board
Andrew Maas - - Member of Medical & Scientific Advisory Board
Zoltan Nagy - - Member of Medical & Scientific Advisory Board
Rick Strassman - - Member of Medical & Scientific Advisory Board
Steven L. Wolf - - Member of Medical & Scientific Advisory Board
Peter Dicpinigaitis - 2023 Medical Consultant of Chronic Cough Research Prgm. & Member of Medical and Scientific Advisory Board
Ede Frecska - - Member of Medical & Scientific Advisory Board
Robert Simister - - Member of Medical & Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AGN Comments

Write your thoughts about Algernon Pharmaceuticals Inc Class A
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email